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RESPECT have all found a statistically significant benefit in the intention-to-treat population for PFO closure compared with medical management. [8] [9] [10] Younger patients with strokes have the potential to accrue more costs over their lifetime both from disability and lost income. Hence, therapies that reduce stroke recurrences in this population are vitally important. Although multiple randomized trials have now demonstrated the efficacy of PFO closure, it is costly and associated with some complications in an otherwise younger, healthier stroke population. The objective of this study was to determine the cost-effectiveness of PFO closure after cryptogenic stroke compared with conservative medical management in the United States from a healthcare payer perspective using a model based on the meta-analysis of the 5 randomized clinical trials, with a 15-year time horizon.
Methods

Overview
The authors declare that all supporting data are available within the article. A previously published decision analytic model was adapted in Microsoft Excel to analyze the cost-effectiveness of PFO closure in addition to antiplatelet medication compared with medical therapy alone (ie, antiplatelet, anticoagulation, or both) for the secondary prevention of strokes. 11 We combined outcome and procedural complication data from all 5 randomized clinical trials: CLOSURE I, RESPECT (the planned analysis), PC, REDUCE, and CLOSE. Institutional review was exempted because this study used only previously published data.
Model Structure
Patients with PFO enter the model after a stroke, transient ischemic attack (TIA), or systemic emboli. Overwhelmingly, the most common event was a cryptogenic stroke (93% of the patients across all 5 trials), but 2 earlier trials, CLOSURE I and PC, also included some patients with TIA and systemic emboli, respectively. All patients were assumed to be 45 years old at the time of index event, which was the mean age among patients in the first 3 trials (CLOSURE I, RESPECT, and PC), using patient-level meta-analysis. 7 Stroke disability is quantified using the modified Rankin Scale (mRS) score, with mRS score 0 indicating no symptoms; mRS score 1, no significant disability; mRS score 2, minor disability; mRS score 3, moderate disability; mRS score 4, moderate to severe disability; mRS score 5, severe disability; and mRS score 6, death. The decision tree analyzes the cost of a complication associated with PFO closure, including device and procedural complications, atrial fibrillation, and procedural death ( Figure 1A ). It is possible to find incidental atrial fibrillation after randomization in the medical group, which would be unrelated to PFO closure.
In our previous model assessing the efficacy of intra-arterial thrombectomy after acute stroke, we had broken down each mRS as a discrete Markov state. 11 However, unlike interventional therapy, which ameliorates disability of strokes, we assume that PFO closure does not lessen the severity of subsequent strokes compared with nonclosure. Because the distribution of disability in each arm is the same, we opted for a simpler Markov model consisting of 4 Markov states. All patients entered the Markov model, where they remained healthy, suffered a stroke and is independent (mRS score 0-2), suffered a stroke and is dependent (mRS score 3-5), or died ( Figure 1B) . Patients with dependent strokes cannot lose their disability but can die, whereas patients with nondependent strokes may suffer another stroke and become dependent or die.
In the RESPECT trial, only 13% of recurrent strokes in those >60 years old were cryptogenic, compared with 82%, which were cryptogenic in subjects ≤60 years. 12 The mean age of patients entering this model is 45 years old, so we chose a time horizon of 15 years to avoid confounding of strokes because of other etiologies. The cycle length is 1 year. Death is the only absorbing state, after which patients were excluded from the model.
Input Parameters
Model input parameters were drawn from published literature, the meta-analysis of trials, and the National Inpatient Sample (Table) . This study used only costs based on actual patient data in the United States. Whenever possible, this study relied on assumptions used in prior peer-reviewed cost-effectiveness analysis models to enhance the validity of these findings and to maximize comparability to other stroke treatments.
Probabilities
Because of the heterogeneity of the medical arm (anticoagulation, antiplatelet, or both), we calculated the annualized stroke rate in the more homogenous PFO closure arm (closure plus antiplatelet in all trials) and applied the inverse hazard ratio of closure from the meta-analysis, assuming random effects (Figure 2 ), to get the annualized stroke rate of the medical arm. Annualized rates of stroke in both arms were converted into an annual probability for the model. The probabilities of procedural complications and atrial fibrillation were taken from the meta-analysis. The most common complications (n>2) were major bleeding, cardiac thrombus, cardiac tamponade, stroke, and device dislocation. There were no deaths directly because of PFO closure and no deaths from recurrent strokes; however, these variables were included to test their potential influence on cost-effectiveness, and a small sensitivity range was introduced. Two of the 5 trials, CLOSE and RESPECT, reported functional outcomes after recurrent strokes. In CLOSE, 1 of 14 (7.1%) recurrent strokes had an mRS score >2. 8 In RESPECT, 9 of 25 (36%) recurrent stroke had an mRS score >2. 12 Altogether, the risk of stroke with dependence (mRS score >2) was 25.6%. However, because of the relatively small sample, we introduced an even wider sensitivity range between 7% and 45% to account for this uncertainty (which is larger than would be expected using a beta distribution with alpha of 10 and beta of 29). We assumed the same probability of disabling recurrent strokes in both the treatment and medical arms.
Cost
The cost of acute stroke hospitalization was taken from previous literature using US nationwide estimates for patients <65 years old broken down by discharge disposition, a surrogate for stroke severity. 17 Because of the variability of private health insurance reimbursement in the United States, the cost of PFO closure was tabulated from standard Medicare reimbursement rates. 20 Charges for PFO closure include 2 echocardiograms, 2 outpatient visits, and percutaneous transcatheter closure as an outpatient (see Table I in the online-only Data Supplement). Cost of closure complications were estimated based on the proportion of a complication multiplied by its associated national average cost identified by the International Classification of Disease-9 code (see Table II in the online-only Data Supplement). 21 The additional cost of atrial fibrillation or flutter assumes the cost of warfarin treatment for 15 years or the time horizon of the model. 18 Annual post-hospitalization costs based on mRS were taken from a previously published stroke model based on a cohort of 958 acute stroke patients in US centers with strokes between 2010 and 2014. 19 All future costs were discounted by 3% per year, consistent with current guidelines. 22 All costs before 2017 were inflated to 2017 US Dollars according to the medical care component of the Consumer Price Index.
Outcome Assessment
Utility for each Markov state, including healthy (mRS score 0), stroke without dependence (mRS score 0-2), stroke with dependence (mRS score 3-5), and death ranged from 0 to 1, where a utility of 1 represents no loss of utility and 0 is death or no utility at all. Utility values were taken from previously validated stroke models using the same health states. 14 Respective utilities at the end of each cycle were summed over the time horizon to get quality-adjusted life years (QALYs). Future QALYs were discounted by 3% per year, in accordance with current guidelines. 22 The incremental cost and QALY between PFO closure and medical treatment were assessed. The incremental cost-effectiveness ratio was obtained by dividing the cost difference by the difference in QALY. This is commonly interpreted as the cost per an additional QALY gained. A treatment producing benefit in QALY and cost saving is referred to as the dominant strategy. Given that negative incremental cost-effectiveness ratios are hard to interpret, we also calculated the incremental net monetary benefit (INMB) of treatment given by the equation: (difference in QALY)×WTP−(difference in cost). 23 The interpretation of INMB is intuitive, where a positive value indicates cost-effective and negative if not. Because patients enter the model at 45 years of age, during their prime working years, we set the higher willingness-to-pay (WTP) threshold of $150 000 per QALY, based on current recommendations for the United States.
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Sensitivity Analysis
To estimate the uncertainty of each input parameter on model results, we used a deterministic one-way sensitivity analysis. All input parameters, including transitional probabilities, health utilities, hazard ratios, and costs, were varied by a prespecified sensitivity range. Values derived by the meta-analysis, including probabilities of procedural complications, probability of atrial fibrillation or flutter in both arms, and hazard ratio of nonclosure, were varied by their 95% confidence intervals. Death hazard ratios after stroke and health utilities were varied based on consensus of an expert panel, and all cost variables were varied by a magnitude of 0.5 and 2.
A probabilistic sensitivity analysis using Monte Carlo simulation was performed, in which all input parameters were varied simultaneously, with mean defined as the base case and range defined as 2 SD from the mean in either direction. Transitional probabilities and health state utilities all varied by a beta distribution. Hazard ratios varied by log normal distribution. All costs were varied using a gamma distribution. The analysis was run 10 000 times to capture stability in the results. Uncertainty was represented using a scatter plot. Because the time horizon can change depending on the age of the patient at the time of treatment, we also represented the probability of costeffectiveness in a surface plot with varying time horizon and WTP. 
Results
Base-Case Analysis
One-Way Sensitivity Analysis
With the exception of the hazard ratio of recurrent stroke, variation across all other variables still resulted in acceptable limits of cost-effectiveness, defined as WTP of $150 000 (Figure 3) . The model was most sensitive to the hazard ratio of stroke with closure or the magnitude of treatment benefit. With the high hazard ratio estimate of 0.77, indicating less benefit from closure, the INMB became negative, costing $10 150, with incremental cost-effectiveness ratio of $458, 58 per additional QALY. On the other extreme, with a hazard ratio of 0.13, the INMB increases to $155 849, producing an improvement of 0.98 in QALY and $44 944 in cost savings.
Multiway Probabilistic Sensitivity Analysis
The results of the multiway sensitivity analysis are shown in Figure 4 . In 57.8% of the simulations run, PFO closure was the dominant strategy with a benefit in QALYs and cost savings. In 97.7% of the simulations run, PFO closure was beneficial, with more QALYs than medical therapy. Finally, in 90.0% of the simulations, PFO closure was cost-effective at a WTP threshold of $150 000/QALY. The 95% interval for INMB at a WTP of $150 000 ranged from −$8284 to $158 910. The surface plot in Figure 5 demonstrates the probability of costeffectiveness based on the WTP and the time horizon or years after PFO closure. For example, at WTP of $50 000, we would attain a probability of >90% cost-effectiveness by 25 years. As expected, the probability of cost-effectiveness increased with longer time and increased threshold for WTP. 
Discussion
We found that in the United States, PFO closure compared with medical therapy alone is a cost-effective secondary prevention strategy in young to middle-aged patients with cryptogenic stroke. PFO closure surpassed our preset WTP threshold of $150 000, leading to better cost and QALY outcomes and an INMB of $52 761 in the base case.
The only parameter that would make PFO closure no longer cost-effective would be a decline in treatment effectiveness from a hazard ratio in the base case of 0.32 (or number needed to treat 95/year) to a hazard ratio at or above 0.64 (number needed to treat 345/ year). Of the 5 trials, only CLOSURE I exceeded the hazard ratio of 0.64, likely because of their inclusion of patients with TIA and lacunar strokes. 4 In fact, the majority of recurrent strokes were because of etiologies other than paradoxical embolus. In addition, there are concerns regarding the efficacy of the STARFlex Septal Closure System, which is now off the market in the United States. In contrast, PC, RESPECT, CLOSE, and REDUCE only included patients with radiographic strokes, though 2.5% of 
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patients in the PC trial had index events of systemic embolus.
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In the most efficacious trial, CLOSE (hazard ratio 0.03, number needed to treat 7/yr), only patients with atrial septal aneurysm or large shunt were enrolled. This magnitude of benefit was also seen in a subgroup of RESPECT with similar PFO characteristics. We chose to include all trials in this analysis to avoid bias, given the small number of published trials. These trial differences emphasize the need to more concisely define which patient populations will benefit most from PFO closure. To our knowledge, there is one previously published costeffectiveness model evaluating PFO closure. 25 They used pooled results from the first 3 trials (CLOSURE I, PC, and RESPECT) and found a cost of $50 692 per QALY at 2.6 years. There are a few notable differences. First, TIA was used as an outcome, and because there is no clinical test for TIA, it is generally an unreliable outcome to assess. Next, the utility of 0.52 assessed for every stroke may be overly pessimistic in this young population, which tends to have better recover. 26 Finally, the hazard ratio of stroke with closure was 0.7, resulting in a quicker onset of cost-effectiveness but longer time to reach dominance with PFO closure (30.2 years).
Procedure-related atrial fibrillation could affect the longer term cost-effectiveness of PFO closure, as atrial fibrillation could be an independent cause of strokes. Overall, atrial fibrillation was significantly more common in the closure arm than the medical arm. In CLOSURE I, 23 patients developed atrial fibrillation in the closure arm, 17 of which were transient and 6
were persistent. 4 Similarly in CLOSE, only 3 of 11 patients who developed atrial fibrillation in the closure arm required continued anticoagulation, 8 and in RESPECT, periprocedural atrial fibrillation was transient without recurrence. The risk of atrial fibrillation in the control arm was not zero in any trial, so there must be a proportion of patients in the closure arm that would have developed atrial fibrillation regardless of the procedure. Certainly, there is a significant risk of closure-induced atrial fibrillation, but whether this persists years after closure or if it is transient remains unclear. Hence, an initial cost and penalty of QALY for atrial fibrillation was taken at the beginning of this model without speculation into any potential later implications.
This model evaluates PFO closure from the healthcare payer perspective, and additional costs such as loss of productivity were not accounted for. While the average age of first ischemic stroke in the United States is 69 to 72 years, the average age of patients entering this model is 45. 27 Unlike previous cost-effectiveness models on stroke, these individuals are more likely to be in the prime of their careers, and stroke likely results in significant loss of potential income. 28 Although the mRS is useful for grading stroke disability, it is biased toward gross motor disabilities. For example, a high functioning executive who has slowed processing speeds after stroke may have mRS score 1 (slight disability, able to carry out usual tasks) but be unable to perform her previous job. Given these considerations, we chose the higher WTP threshold of $150 000/QALY, which has been recommended for the United States. 24 There are some limitations to this study. First, we assume that patients entered the model with a quality of life utility of 1 instead of discounting for the initial stroke. This is because there is no data on utility after a cryptogenic stroke in younger patients nor on the utility after a recurrent stroke in this population. We introduced a wide sensitivity range to account for this uncertainty. To calculate the penalties from procedural complications, we elected to use utilities complied in a large single source, which may not be the most up to date, instead of drawing from numerous disparate sources. 13 Second, this economic evaluation is intended for young to middle-aged cryptogenic stroke patients for whom the effects of atherosclerotic risk factors are not yet a major consideration. We do not factor in strokes from other causes, whose greater incidence would likely overshadow strokes from PFO later in life and overwhelm any benefit from PFO closure. Third, we estimated PFO procedural costs using the atrial septal defect closure procedural code, which it is usually billed under. Although patients in this population are not yet old enough for Medicare, we used standardized Medicare costs because individual insurance plans can vary widely. Finally, cost of long-term care was attained for an older stroke population and may not accurately reflect costs in a younger population.
In conclusion, PFO closure for cryptogenic strokes in the right setting is cost-effective, producing benefit in QALYs and cost savings. However, patient selection remains vitally important as marginal declines in treatment effectiveness can dramatically affect cost-effectiveness. In this setting, a multidisciplinary evaluation by a vascular neurologist in addition to the cardiologist may be helpful. Further work is needed to evaluate PFO closure in older adults and to more definitively identify, through patient-level meta-analysis, subgroups that may derive more benefit from treatment such as larger PFOs, presence of an atrial septal aneurysm, or a venous hypercoagulability. 
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